pSILAC mass spectrometry reveals ZFP91 as IMiD-dependent substrate of the CRL4CRBN ubiquitin ligase
暂无分享,去创建一个
Michael B. Stadler | J. Seebacher | R. Sack | E. Fischer | K. Donovan | Jian An | Charles M. Ponthier | E. S. Fischer
[1] Nobuhiro Nakamura,et al. Ubiquitin System , 2018, International journal of molecular sciences.
[2] Chin-Chun Lu,et al. A novel cereblon modulator recruits GSPT1 to the CRL4CRBN ubiquitin ligase , 2016, Nature.
[3] B. Kuster,et al. Immunomodulatory drugs disrupt the cereblon–CD147–MCT1 axis to exert antitumor activity and teratogenicity , 2016, Nature Medicine.
[4] G. Petzold,et al. Structural basis of lenalidomide-induced CK1α degradation by the CRL4CRBN ubiquitin ligase , 2016, Nature.
[5] W. I. Mohamed,et al. Cullin–RING ubiquitin E3 ligase regulation by the COP9 signalosome , 2016, Nature.
[6] Justin M. Reitsma,et al. Glutamine Triggers Acetylation-Dependent Degradation of Glutamine Synthetase via the Thalidomide Receptor Cereblon. , 2016, Molecular cell.
[7] B. Ebert,et al. Lenalidomide: deciphering mechanisms of action in myeloma, myelodysplastic syndrome and beyond. , 2015, Current opinion in cell biology.
[8] Dennis L. Buckley,et al. Small-Molecule-Mediated Degradation of the Androgen Receptor through Hydrophobic Tagging. , 2015, Angewandte Chemie.
[9] I. E. Smith,et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. , 2015, Nature chemical biology.
[10] Michael B. Stadler,et al. Analysis of intronic and exonic reads in RNA-seq data characterizes transcriptional and post-transcriptional regulation , 2015, Nature Biotechnology.
[11] I. E. Smith,et al. HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins. , 2015, ACS chemical biology.
[12] James E. Bradner,et al. Phthalimide conjugation as a strategy for in vivo target protein degradation , 2015, Science.
[13] C. Crews,et al. Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. , 2015, Chemistry & biology.
[14] S. Carr,et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS , 2015, Nature.
[15] A. Lamond,et al. Multidimensional proteomics for cell biology , 2015, Nature Reviews Molecular Cell Biology.
[16] G. von Heijne,et al. Tissue-based map of the human proteome , 2015, Science.
[17] Matthew E. Ritchie,et al. limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.
[18] Michael B. Stadler,et al. QuasR: quantification and annotation of short reads in R , 2014, Bioinform..
[19] H. Handa,et al. Structure of the human Cereblon–DDB1–lenalidomide complex reveals basis for responsiveness to thalidomide analogs , 2014, Nature Structural &Molecular Biology.
[20] Jeremy L. Jenkins,et al. Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide , 2014, Nature.
[21] Edward L. Huttlin,et al. MultiNotch MS3 Enables Accurate, Sensitive, and Multiplexed Detection of Differential Expression across Cancer Cell Line Proteomes , 2014, Analytical chemistry.
[22] Edward L. Huttlin,et al. Quantitative Temporal Viromics: An Approach to Investigate Host-Pathogen Interaction , 2014, Cell.
[23] Guang-Biao Zhou,et al. Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer. , 2014, Carcinogenesis.
[24] Christopher J. Ott,et al. The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins , 2014, Science.
[25] S. Carr,et al. Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells , 2014, Science.
[26] D. Toczyski,et al. Ubiquitin ligase trapping identifies an SCF(Saf1) pathway targeting unprocessed vacuolar/lysosomal proteins. , 2014, Molecular cell.
[27] H. Handa,et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4CRBN , 2013, British journal of haematology.
[28] Céline Hernandez,et al. A Novel Pulse-Chase SILAC Strategy Measures Changes in Protein Decay and Synthesis Rates Induced by Perturbation of Proteostasis with an Hsp90 Inhibitor , 2013, PloS one.
[29] J. Harper,et al. Parallel SCF adaptor capture proteomics reveals a role for SCFFBXL17 in NRF2 activation via BACH1 repressor turnover. , 2013, Molecular cell.
[30] John R. Yates,et al. Identification of Long-Lived Proteins Reveals Exceptional Stability of Essential Cellular Structures , 2013, Cell.
[31] Derek J. Bailey,et al. Neutron-encoded mass signatures for multi-plexed proteome quantification , 2013, Nature Methods.
[32] J. Harper,et al. Understanding Cullin-RING E3 Biology through Proteomics-based Substrate Identification* , 2012, Molecular & Cellular Proteomics.
[33] M. Rapé,et al. The Ubiquitin Code , 2012, Annual review of biochemistry.
[34] Steven P Gygi,et al. Hyperplexing: A Method for Higher-Order Multiplexed Quantitative Proteomics Provides a Map of the Dynamic Response to Rapamycin in Yeast , 2012, Science Signaling.
[35] Davis J. McCarthy,et al. Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation , 2012, Nucleic acids research.
[36] Michelle S. Scott,et al. A Quantitative Spatial Proteomics Analysis of Proteome Turnover in Human Cells* , 2011, Molecular & Cellular Proteomics.
[37] M. Selbach,et al. Global quantification of mammalian gene expression control , 2011, Nature.
[38] Xuejun Jin,et al. Zinc-finger protein 91 plays a key role in LIGHT-induced activation of non-canonical NF-κB pathway. , 2010, Biochemical and biophysical research communications.
[39] Xuejun Jin,et al. An Atypical E3 Ligase Zinc Finger Protein 91 Stabilizes and Activates NF-κB-inducing Kinase via Lys63-linked Ubiquitination* , 2010, The Journal of Biological Chemistry.
[40] Ruedi Aebersold,et al. Options and considerations when selecting a quantitative proteomics strategy , 2010, Nature Biotechnology.
[41] Toshihiko Ogura,et al. Identification of a Primary Target of Thalidomide Teratogenicity , 2010, Science.
[42] R. Deshaies,et al. RING domain E3 ubiquitin ligases. , 2009, Annual review of biochemistry.
[43] D. Moras,et al. A set of baculovirus transfer vectors for screening of affinity tags and parallel expression strategies. , 2009, Analytical biochemistry.
[44] M. Mann,et al. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.
[45] Magda Melchert,et al. The thalidomide saga. , 2007, The international journal of biochemistry & cell biology.
[46] J. Harper,et al. Ubiquitin proteasome system (UPS): what can chromatin do for you? , 2007, Current opinion in cell biology.
[47] Angus G. Dalgleish,et al. The evolution of thalidomide and its IMiD derivatives as anticancer agents , 2004, Nature Reviews Cancer.
[48] Andrew H. Thompson,et al. Tandem mass tags: a novel quantification strategy for comparative analysis of complex protein mixtures by MS/MS. , 2003, Analytical chemistry.
[49] Terence P. Speed,et al. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias , 2003, Bioinform..
[50] M. Mann,et al. Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics* , 2002, Molecular & Cellular Proteomics.
[51] B. Barlogie,et al. Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.